ProCE Banner Activity

CE / CME

Q&A: Optimal Management of Moderate to Severe Atopic Dermatitis in Tweens and Teens

Clinical Thought

Expert faculty answer questions about management of moderate to severe atopic dermatitis with comorbidities in tweens and teens.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Released: February 09, 2023

Expiration: February 08, 2024

No longer available for credit.

Share

Faculty

Robert Sidbury

Robert Sidbury, MD, MPH

Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Childrens Hospital
University of Washington School of Medicine
Seattle, Washington

Jonathan Silverberg

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Sanofi Genzyme

Target Audience

This education is intended for dermatologists, allergists, nurse practitioners, physician associates/physician assistants, nurses, and other healthcare professionals who treat pediatric and adult patients with moderate to severe atopic dermatitis.

Program Learning Goal

The goal of this educational program is to improve learners’ knowledge and competence regarding improving the management of pediatric and adult patients with moderate to severe atopic dermatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review efficacy and safety data for infants and young children, tweens and teens, and adults with moderate to severe AD

  • Select optimal therapy for patients with moderate to severe AD based on indication and efficacy and safety data

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Robert Sidbury, MD, MPH

Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Childrens Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH: consultant/advisor/speaker: Beiersdorf, Leo, Lilly, Micreos; researcher: Castle, Galderma, Pfizer, Regeneron, UCB.

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Jonathan Silverberg, MD, PhD, MPH: consultant/advisor: AbbVie, Aobiome, Amgen, Arcutis, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Lilly, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Union.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristine Kucera, PA-C, MPAS, DHSc and Victoria Garcia-Albea, NP, DCNP, as noted below:

Kristine Kucera, PA-C, MPAS, DHScconsultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol-Myers Squibb, Dermavant, Leo, Novartis, Sun, UCB.

Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until February 8, 2024. PAs should only claim commensurate with the extent of their participation.